KRAS
HealthRevolutionary new drug targets hard-to-treat cancers – helping millions world-wide
Researchers discover that ACBI3, a new drug targeting KRAS mutations, shows promise in treating multiple cancer types.
Joshua Shavit
Researchers discover that ACBI3, a new drug targeting KRAS mutations, shows promise in treating multiple cancer types.
Joshua Shavit